Home phototherapy has always presented a monitoring problem. The clinical case for NB-UVB as a home modality is well established — the safety profile is excellent, patient adherence to home-based treatment compares favourably to clinic attendance for a three-to-five-times-weekly therapy, and outcomes data from home phototherapy programmes are consistent with clinic-based equivalents when dosimetry is properly controlled.
The problem is not the therapy. It is the visibility gap that opens up between your clinic appointments and your patient's treatment sessions.
In a clinic setting, every session is an implicit monitoring event. You or a nurse sees the patient, observes the treated skin, assesses the response, and makes adjustments. At home, the patient treats themselves — correctly or incorrectly, consistently or sporadically, with a device that may or may not be delivering what it claims — and you see them again four, six, or eight weeks later. The information you receive at that appointment is filtered through self-report, which is inherently limited in precision and reliability.
Closing this visibility gap is the clinical challenge of home phototherapy monitoring. This guide covers what to track, what data sources to use, and how to structure remote oversight that is meaningful rather than performative.
The Four Domains of Home Phototherapy Monitoring
Effective monitoring of a patient on home NB-UVB covers four distinct domains, each with different data requirements and different clinical implications when things deviate from expected.
1. Dose Delivery: What the Patient Is Actually Receiving
This is the most fundamental monitoring parameter and the most commonly absent from home phototherapy oversight.
There is a critical distinction between what a patient has been prescribed and what their device is delivering. In timer-based devices — which remain common in the home phototherapy market — dose is controlled by session duration, not by measured UV output. A patient prescribed a 30-second session at the start of treatment and a 90-second session at month three is receiving a prescribed time, not a prescribed dose.
UV lamp output degrades with use. The Philips TL/01 and equivalent NB-UVB lamps lose output progressively over their lifespan — the rate of degradation varies by usage pattern, but output reductions of 20–40% over a treatment course of several months are not uncommon. A timer-based device has no mechanism to detect or compensate for this. The patient continues treating for the prescribed duration while receiving a progressively declining fraction of the prescribed mJ/cm² — with no indication to either patient or clinician that their effective dose has fallen.
What to monitor: For patients using devices with dosimetry capabilities — real-time UV sensor measurement with dose delivery recorded in mJ/cm² per session — your monitoring record should include actual dose delivered per session, cumulative dose over the treatment course, and any divergence between prescribed and delivered dose. This data should be available remotely, either through a connected app or exported session log.
If a patient is using a timer-based device, you are monitoring adherence (did they treat?) but not dosimetry (did they receive the prescribed dose?). This is a meaningful clinical limitation that should be documented. Where possible, transitioning patients to devices with dosimetry capabilities is worth recommending specifically on monitoring grounds.
Red flags: Sessions where reported duration does not produce the expected dose in mJ/cm² — suggesting lamp degradation. Sudden step changes in effective dose. Prolonged gaps between sessions followed by immediate resumption at the most recent dose without dose reduction.
2. Adherence: The Frequency and Consistency of Treatment
NB-UVB efficacy is cumulative and frequency-dependent. The evidence base for the condition-specific outcomes your patient is expecting is built on three-to-five sessions per week. Significant deviation from this — particularly in the critical early months — substantially reduces the probability of achieving the response the protocol is designed for.
Self-reported adherence is unreliable, not because patients are dishonest but because recall of treatment frequency is genuinely imprecise and because patients have an incentive (conscious or not) to report better adherence than they have maintained.
What to monitor: Session timestamps with actual treatment dates — not self-reported summaries. A patient who tells you "I've been doing it regularly" and whose device log shows nine sessions in the past four weeks (averaging twice weekly rather than three times) has different adherence from what the self-report implies, and their dose escalation schedule should reflect that reality.
Calculate adherence as a percentage of expected sessions per monitoring period. For a four-week period on a three-times-weekly protocol, expected sessions are twelve. Delivered sessions of eight represent 67% adherence — a meaningful deviation that warrants a conversation, not necessarily protocol adjustment, but exploration of whether the barrier is practical (schedule, family, device setup) or motivational (patient has not seen expected progress and is disengaging).
Adherence patterns to distinguish:
Consistent low adherence — the patient is treating one to two times per week across the monitoring period. This requires a conversation about whether the frequency commitment is realistic and whether the protocol needs adjustment to what the patient can actually sustain.
Clustered adherence — the patient is treating in bursts (four days in a row, then a ten-day gap, then four more days). This is a different problem from consistent low frequency and may reflect practical barriers such as travel or work schedule rather than motivational issues.
Declining adherence over time — a patient who began at appropriate frequency and has progressively treated less often. This is the classic mid-course dropout pattern and is often preceded by a subjective sense of insufficient progress. Early identification allows intervention before the patient has stopped entirely.
3. Clinical Response: Objective Assessment Between Visits
Patient self-report of response is even less reliable than self-report of adherence. Patients who are anxious about their condition tend to underestimate progress. Patients who were highly motivated at baseline tend to overestimate early signs of response. Neither provides the objective assessment you need to make protocol decisions.
Standardized photography is the practical solution to remote response assessment and is the monitoring modality with the highest ratio of clinical value to patient burden. A photograph taken in consistent lighting, from a fixed angle, with a reference landmark in frame, at two-weekly intervals, gives you an objective visual record that allows direct comparison — something no verbal description or patient self-assessment can replicate.
What you are looking for:
In vitiligo: perifollicular repigmentation — the small pigmented dots around hair follicle openings within depigmented patches — appearing at weeks eight to twelve in a patient on an adequate dose and appropriate frequency. Their presence at this stage is a reliable positive predictor. Their absence at week sixteen in a patient with confirmed adequate dosimetry and appropriate adherence should prompt protocol review. Pay attention to the distribution of response across body areas — facial and truncal patches may show response while acral patches do not; this should be communicated to the patient in advance rather than interpreted as treatment failure.
In psoriasis: plaque thinning and reduction in erythema beginning at weeks four to six. Photographs should capture the full extent of representative plaques, not individual lesion close-ups, to allow PASI-consistent visual assessment of percentage area change over time.
In atopic dermatitis: the most useful photographic assessment combines images of representative affected areas with patient-reported itch scores (NRS or POEM questionnaire scores). Skin appearance can lag significantly behind symptomatic improvement in AD — patients who are sleeping better and experiencing less itch but show unchanged-appearing skin on photographs are responding, and framing this correctly prevents discouragement.
Structured patient-reported outcomes — POEM for atopic dermatitis, DLQI for quality of life — administered digitally at regular intervals provide quantitative trends that supplement photographic assessment and make change over time legible in a way that one-off clinic assessments cannot.
4. Safety: Detecting Adverse Events Between Visits
The NB-UVB safety profile is excellent. Significant adverse events are uncommon in appropriately selected patients treated on correct protocols. But they do occur, and most are preventable with early detection and dose adjustment.
What to monitor between visits:
Erythema severity and duration. A degree of post-treatment pinkness is expected and acceptable — it indicates an appropriate UV response and is not a cause for concern. The clinical concern is erythema that is intense, painful, or persists beyond 24 hours. Patients should be instructed to photograph and report any post-treatment skin reaction that meets these criteria, and your monitoring system should have a clear pathway for them to do so.
Eye symptoms. Any patient reporting photophobia, eye pain, or vision changes during or after treatment should be assessed urgently. UV eye protection is mandatory during treatment and should have been verified at setup.
New or changed skin lesions. Patients on longer treatment courses should be told to photograph and report any new pigmented or non-pigmented lesion appearing in the treated area that was not present at baseline.
Medication changes. Several medications — including common antibiotics, antifungals, and diuretics — are photosensitising and can substantially increase erythema risk at doses that were previously well-tolerated. Remote monitoring should include a prompt for patients to report new medications, and you should check photosensitisation risk when any new prescription is added.
Structuring the Monitoring Protocol
The practical implementation of home phototherapy monitoring requires three things: a data collection system, a review cadence, and defined escalation thresholds.
Data collection. The minimum viable remote monitoring dataset is: session log with timestamps, dose delivered in mJ/cm² (if the device supports dosimetry), fortnightly photographs, and a monthly patient-reported outcome measure. This is achievable without sophisticated technology — a shared folder for photographs and a structured check-in message would cover most of it. Connected phototherapy apps that integrate session data, photography, and patient messaging make this substantially more practical at scale.
Review cadence. The monitoring intensity should be highest at the beginning of a treatment course and can be reduced as a patient establishes a stable pattern. A suggested structure:
Weeks 1–4: Remote check-in at week two. Confirm session log is being kept, device setup is correct, no adverse events. Review initial photographs.
Weeks 4–12: Fortnightly photograph review. Monthly patient-reported outcome measure. Flag any adherence deviation.
Week 12: Formal response assessment. Review cumulative dose data, photograph comparison from baseline, adherence record, and patient-reported outcomes. Decision: continue current protocol, adjust dose escalation, or reassess indication.
Post-week 12: Monthly review for stable responders. Return to fortnightly for patients with incomplete response or adherence concerns.
Escalation thresholds. Define these explicitly with your patient at the start of treatment and document them:
Erythema persisting beyond 24 hours or rated as painful → contact clinic before next session
More than two consecutive sessions missed → patient initiates check-in
No visible perifollicular response by week 14 in vitiligo with confirmed adequate dosimetry → clinic review appointment
Any new symptom in treated area → photograph and message same day
The Visibility Gap, Closed
Home phototherapy monitoring does not require a clinic visit to be clinically meaningful. What it requires is structured, objective data — session logs with actual doses rather than self-reported summaries, photographs taken to a consistent standard, patient-reported outcomes at defined intervals, and a clear pathway for patients to flag adverse events before their next appointment.
The tools to collect this data are available. The clinical value of doing so is direct: patients on home NB-UVB who are monitored objectively — with real dosimetry data and regular photograph review — are treated differently and better than those managed on self-report alone. Protocol adjustments are made at the right time. Non-response is identified before a patient has invested six months in a failing course. Lamp degradation is caught before it has silently undermined weeks of treatment.
The visibility gap between clinic visits is where home phototherapy outcomes are won or lost. Structured monitoring is what closes it.
UVThera provides dermatologists with a clinician dashboard giving direct access to patient session data — dose delivered in mJ/cm², session timestamps, device lamp status, and progress photographs — updated in real time between clinic appointments. For dermatology practices prescribing home phototherapy, the dashboard is available as part of the UVThera clinical programme. Contact us →
UVThera home devices are CDSCO Class B registered. Developed at SINE, IIT Bombay.